🏠 News Empire
health

Former Delhi Health Services Chief Arrested in Rs 350 Crore Procurement Scam

Published on: 28 Jun 2026, 04:47 AM
Former Delhi Health Services Chief Arrested in Rs 350 Crore Procurement Scam

The Delhi government’s Anti-Corruption Branch (ACB) on Thursday arrested Dr Vatsala Agarwal, former Director General of Health Services (DGHS), in connection with an alleged procurement scam involving medicines, surgical supplies, and medical equipment worth Rs 350 crore.

Dr Agarwal was taken into custody as part of the ACB’s ongoing investigation into financial irregularities in government procurement processes. Earlier, on June 19, the ACB had arrested Dr Vijay Kumar Ranga in the same case. Following his arrest, investigators questioned Dr Ranga to probe the alleged irregularities and the roles of other officials involved.

According to ACB officials, the alleged scam is linked to the procurement of medicines, surgical items, and medical equipment through the Central Procurement Agency (CPA), which operates under the Directorate General of Health Services (DGHS). The procurement contracts, worth several hundred crore rupees, are under scrutiny for possible violations of norms and procedural lapses.

The arrests are part of a broader effort by the ACB to examine corruption in the healthcare sector. Authorities have not yet provided details on the specific nature of the irregularities or named any other suspects. Investigations are ongoing to determine the extent of the fraud and identify additional individuals or entities involved.

The case highlights concerns about governance and transparency in public health procurement systems. The Delhi government has stated its commitment to ensuring accountability and has promised strict action against those found guilty.

Latest in Health 10
Health Ministry Proposes Easier Drug Import Rules for Testing and R&D
health

Health Ministry Proposes Easier Drug Import Rules for Testing and R&D

The Union Health Ministry proposes to simplify import procedures for drugs used in testing and R&D, replacing licensing with an acknowledgement-based system. A separate amendment rationalises residual shelf-life requirements for imported drugs to 12 months, aiming to reduce wastage and improve supply chain efficiency.

The Hindu 27 Jun 2026, 04:47 AM
Read More →
→ View All Health News